Antenatal prophylaxis of acute digestive disorders in calves

Among the diseases of young cattle of non-contagious aetiology, an important place is occupied by the pathology of the digestive system. In particular, dyspepsia, casein-bezoar disease, colostrum toxicosis, and diarrhoea are characteristic of the above pathologies. A familiar name, acute digestive disorders, unites these diseases. That is why it is essential to correct the metabolism of calves. The aim of the study is to investigate the effectiveness of antenatal prophylaxis for acute digestive disorders in calves of the neonatal period with the addition of propylene glycol to the diet of cows during the transient period, which increases the amount of propionic acid in the rumen and chlorophyll, which affects lipid metabolism and prevents fatty liver infiltration and ketosis. It was determined that the addition of propylene glycol and Cholin-Chloridum to the diet of cows during the transient period influenced the change in the content of β-hydroxybutyrate (HTA) and the amount of ketone bodies in the blood of animals in the experimental group of animals. In the experimental group of animals, these indicators were lower in the control group, by 35% of β-hydroxybutyrate and 44% by the sum of ketone bodies. During the transient period, especially in the first months after calving, cows experience an energy deficit, so ketone bodies are formed to compensate for glucose deficiency. Since propylene glycol and Cholin- Chloridum increased the glucose concentration in the blood, the need for synthesising ketone bodies decreased

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Triazoline compounds influence on the meat productivity of turkey carcasses

The need to find effective means to improve the quality and production of meat products from poultry farming determines the relevance of the study. The introduction of drugs into the diet can increase the safety of livestock and improve the quality characteristics of poultry meat. The research aims to evaluate the impact of new 1,2,4-triazole derivatives on some blood parameters, as well as meat and slaughter qualities of poultry. The study was conducted between 2022 and 2023 at Odesa State Agrarian University. The trial was conducted to study the effect of new triazoline derivatives GKPF-109 at a dose of 0.5 ml/bird per day on turkey performance and meat quality. The experiment was conducted on Big-6 turkeys aged 1-105 days. The following research methods were used: morphological and biochemical, organoleptic, physicochemical, and statistical. The effects of triazoline derivatives GKPF-109 on organoleptic (appearance, smell, consistency, fat condition, broth quality during meat cooking) and physicochemical studies of turkey meat for microbiological parameters were analysed and investigated following DSTU 3143:2013. The results showed that there was an increase in average daily weight by 13.1%, slaughter yield of gutted carcasses by 12.4%, semi-gutted carcasses by 12.3% and livestock preservation by 4%. An increase in the nutritional value of meat was noted due to an increase in muscle tissue protein by 7.5%, fat by 8.3%, and energy value by 4.8%. The organoleptic, bacteriological, and physicochemical parameters of turkey meat when using triazoline derivatives GKPF-109 in the diet met the requirements of DSTU 3143:2013. It was concluded that the addition of triazoline GKPF-109 derivatives to drinking water enhances haemopoiesis and has antiinflammatory and hepatoprotective effects. The assessment of the quality of broiler turkey meat and broth at the end of the experiment does not allow to assert a decrease in their aroma and taste, which indicates the absence of a negative effect of triazoline derivatives GKPF-109 and methods of their application on the organoleptic characteristics of meat, which should be considered when keeping turkey

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

BACKGROUN